Your Trusted Brand for Over 35 Years

Uterine (Endometrial) Cancer References

Disease Prevention and Treatment, 5th edition

The references on this page correspond with the print version of Disease Prevention and Treatment, 5th edition. Since we continuously update the protocols online in response to new scientific developments, readers are encouraged to review the latest versions of the protocols.

  1. Greenlee RT, Hill-Harmon MB , et al. Cancer statistics: 2001. CA Cancer J Clin . 2001 Jan;51(1):15-36.
  2. McCann SE, Freudenheim JL, et al. Diet in the epidemiology of endometrial cancer in western New York ( United States ). Cancer Causes Control . 2000;11(10):965-74.
  3. Hu FB. Overweight and obesity in women: health risks and consequences. J Womens Health (Larchmt) . 2003 Mar;12(2):163-72.
  4. Schapira DV. Nutrition and cancer prevention. Prim Care . 1992;19(3):481-91.
  5. Berstein L, Tsyrlina E, et al. Switching (overtargeting) of estrogen effects and its potential role in hormonal carcinogenesis. Neoplasma . 2002;49(1):21-5.
  6. Doherty JA, Weiss NS, et al. Genetic factors in catechol estrogen metabolism in relation to the risk of endometrial cancer. Cancer Epidemiol Biomarkers Prev . 2005;14(2):357-66.
  7. Persson I, Adami HO, et al. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. BMJ . 1989 Jan 21;298(6667):147-51.
  8. Emons G, Huschmand-Nia A, et al. Hormone replacement therapy and endometrial cancer. Onkologie . 2004;27(2):207-10.
  9. Chen LM, McGonigle KF, et al. Endometrial cancer: recent developments in evaluation and treatment. Oncology ( Williston Park ) . 1999 Dec;13(12):1665-70.
  10. McMeekin DS, Tillmanns T. Endometrial cancer: treatment of nodal metastases. Curr Treat Options Oncol . 2003 Apr;4(2):121-30.
  11. Hill HA, Austin H. Nutrition and endometrial cancer. Cancer Causes Control . 1996a Jan;7(1):19-32.
  12. Pike MC, Pearce CL, et al. Prevention of cancers of the breast, endometrium and ovary. Oncogene . 2004 Aug 23;23(38):6379-91.
  13. Stenchever MA, Droegemueller W, et al. Comprehensive Gynecology. 4th edition. Philadelphia, Pa: Elsevier Health Sciences; 2002.
  14. Montgomery BE, Daum GS, et al. Endometrial hyperplasia: a review. Obstet Gynecol Surv . 2004;59(5):368-78.
  15. Lutz MH, Underwood PB Jr, et al. Endometrial carcinoma: a new method of classification of therapeutic and prognostic significance. Gynecol Oncol . 1978 Feb;6(1):83-94.
  16. Morrow CP, Bundy BN, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol . 1991 Jan;40(1):55-65.
  17. Noumoff JS, Faruqi S. Endometrial adenocarcinoma. Microsc Res Tech . 1993 Jun 15;25(3):246-54.
  18. Juretzka MM, Chi DS, et al. Update on surgical treatment for endometrial cancer. Expert Rev Anticancer Ther . 2005;5(1):113-21.
  19. Purdie DM, Green AC. Epidemiology of endometrial cancer. Best Pract Res Clin Obstet Gynaecol . 2001;15(3):341-54.
  20. Terry P, Baron JA, et al. Lifestyle and endometrial cancer risk: a cohort study from the Swedish Twin Registry. Int J Cancer . 1999;82(1):38-42.
  21. Goodman MT , Hankin JH, et al. Diet, body size, physical activity, and the risk of endometrial cancer. Cancer Res . 1997a;57(22):5077-85.
  22. Hill HA, Eley JW, et al. Racial differences in endometrial cancer survival: the black/white cancer survival study. Obstet Gynecol . 1996b Dec;88(6):919-26.
  23. Connell PP, Rotmensch J, et al. Race and clinical outcome in endometrial carcinoma. Obstet Gynecol . 1999 Nov;94(pt 1):713-20.
  24. Munstedt K, Grant P, et al. Cancer of the endometrium: current aspects of diagnostics and treatment. World J Surg Oncol . 2004 Jul 21;2(1):24.
  25. Banno K, Susumu N, et al. Association of HNPCC and endometrial cancers. Int J Clin Oncol . 2004 Aug;9(4):262-69.
  26. Lipton LR, Johnson V, et al. Refining the Amsterdam Criteria and Bethesda Guidelines: testing algorithms for the prediction of mismatch repair mutation status in the familial cancer clinic. J Clin Oncol . 2004;22(24):4934-43.
  27. Key TJ, Pike MC. The dose-effect relationship between “unopposed” oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br J Cancer . 1988 Feb;57(2):205-12.
  28. Sevelda P, Salzer H. Hormones and cancer: risk-benefit. Gynakol Geburtshilfliche Rundsch . 1998;38(2):61-3.
  29. Grady D, Gebretsadik T, et al. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol . 1995 Feb;85(2):304-13.
  30. Dai D, Albitar L, et al. A therapeutic model for advanced endometrial cancer: systemic progestin in combination with local adenoviral-mediated progesterone receptor expression. Mol Cancer Ther . 2005;4(1):169-75.
  31. Sivridis E, Giatromanolaki A. Prognostic aspects on endometrial hyperplasia and neoplasia. Virchows Arch. 2001 Aug;439(2):118-26.
  32. Abulafia O, Triest WE, et al. Angiogenesis in endometrial hyperplasia and stage I endometrial carcinoma. Obstet Gynecol . 1995 Oct;86(pt 1):479-85.
  33. Bergeron C. Effect of estrogens and antiestrogens on the endometrium. Gynecol Obstet Fertil . 2002 Dec;30(12):933-37.
  34. Dietl J. Actual aspects of endometrial carcinoma. Zentralbl Gynakol . 2002 Jul;124(7):356-61.
  35. Sivridis E, Giatromanolaki A. Endometrial adenocarcinoma: beliefs and scepticism. Int J Surg Pathol. 2004 Apr;12(2):99-105.
  36. Cancer and Steroid Hormone Study. Combination oral contraceptive use and the risk of endometrial cancer. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. JAMA. 1987 Feb 13;257(6):796-800.
  37. Henderson BE, Casagrande JT, et al. The epidemiology of endometrial cancer in young women. Br J Cancer . 1983 Jun;47(6):749-56.
  38. Pike MC. Age-related factors in cancers of the breast, ovary, and endometrium. J Chronic Dis . 1987;40(suppl 2):59S-69S.
  39. Longcope C, Pratt JH, et al. Aromatization of androgens by muscle and adipose tissue in vivo. J Clin Endocrinol Metab . 1978 Jan;46(1):146-52.
  40. Calle EE, Thun MJ. Obesity and cancer. Oncogene . 2004 Aug 23;23(38):6365-78.
  41. Gallup DG, Stock RJ. Adenocarcinoma of the endometrium in women 40 years of age or younger. Obstet Gynecol . 1984 Sep;64(3):417-20.
  42. Chubak J, Tworoger SS, et al. Associations between reproductive and menstrual factors and postmenopausal sex hormone concentrations. Cancer Epidemiol Biomarkers Prev . 2004;13(8):1296-1301.
  43. Hardiman P, Pillay OC, et al. Polycystic ovary syndrome and endometrial carcinoma. Lancet . 2003 May 24;361(9371):1810-2.
  44. Spencer TE, Bazer FW. Biology of progesterone action during pregnancy recognition and maintenance of pregnancy. Front Biosci . 2002 Sep 1;7:d1879-d1898.
  45. Soliman PT, Oh JC, et al. Risk factors for young premenopausal women with endometrial cancer. Obstet Gynecol . 2005 Mar;105(3):575-80.
  46. Ouzounian S, Christin-Maitre S. What is menopause? Rev Prat . 2005 Feb 28;55(4):363-8.
  47. Mourits MJ, De Vries EG, et al. Tamoxifen treatment and gynecologic side effects: a review. Obstet Gynecol . 2001 May;97(pt 2):855-66.
  48. Swerdlow AJ, Jones ME. Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study. J Natl Cancer Inst . 2005;97(5):375-84.
  49. Liao CK, Rosenblatt KA, et al. Endometrial cancer in Asian migrants to the United States and their descendants. Cancer Causes Control . 2003 May;14(4):357-60.
  50. Potischman N, Swanson CA , et al. Dietary associations in a case-control study of endometrial cancer. Cancer Causes Control . 1993;4(3):239-50.
  51. Chiaffarino F, Parazzini F, et al. Diet and uterine myomas. Obstet Gynecol . 1999;94(3):395-98.
  52. Levi F, Franceschi S, et al. Dietary factors and the risk of endometrial cancer. Cancer . 1993;71(11):3575-81.
  53. Armstrong B. Endocrine factors in human carcinogenesis. IARC Sci Publ . 1982;39:193-221.
  54. Bernstein L, Ross RK, et al. Relationship of hormone use to cancer risk. J Natl Cancer Inst Monogr . 1992;12:137-47.
  55. Deslypere JP. Obesity and cancer. Metabolism . 1995 Sep;44(suppl 3):24-27.
  56. Hershcopf RJ, Bradlow HL. Obesity, diet, endogenous estrogens, and the risk of hormone-sensitive cancer. Am J Clin Nutr . 1987 Jan;45(suppl 1):283-9.
  57. Jensen H. Relationship of premorbid state of nutrition to endometrial carcinoma. Acta Obstet Gynecol Scand . 1986;65(4):301-6.
  58. Hofmeister FJ. Endometrial biopsy: another look. Am J Obstet Gynecol . 1974 Mar 15;118(6):773-7.
  59. Minagawa Y, Sato S, et al. Transvaginal ultrasonography and endometrial cytology as a diagnostic schema for endometrial cancer. Gynecol Obstet Invest . 2005;59(3):149-54.
  60. Berek JS, Hacker NF. Practical Gynecologic Oncology. 3rd edition. Hagerstown , Md : Lippincott Williams & Wilkins; 2000.
  61. Lotfallah H, Farag K, et al. One-stop hysteroscopy clinic for postmenopausal bleeding. J Reprod Med . 2005;50(2):101-7.
  62. Nassar A, Fleisher SR, et al. Value of histiocyte detection in Pap smears for predicting endometrial pathology: an institutional experience. Acta Cytol . 2003;47(5):762-7.
  63. Ng AB, Reagan JW, et al. Significance of endometrial cells in the detection of endometrial carcinoma and its precursors. Acta Cytol . 1974 Sep;18(5):356-61.
  64. Robert Y, Launay S, et al. MRI in gynecology. J Gynecol Obstet Biol Reprod ( Paris ) . 2002 Sep;31(5):417-39.
  65. Magrina JF, Weaver AL. Laparoscopic treatment of endometrial cancer: five-year recurrence and survival rates. Eur J Gynaecol Oncol . 2004;25(4):439-41.
  66. Martin R, Kohler U, et al. Determination of steroid hormone receptors with the biochemical DCC method in endometrial cancer and tumor margin-endometrium relations to cellular changes and hormone level. Geburtshilfe Frauenheilkd . 1993 May;53(5):314-20.
  67. Gurpide E. Hormone receptors in endometrial cancer. Cancer . 1981 Jul 15;48(suppl 2):638-41.
  68. Kedzia W. Analysis of steroid hormone receptors in endometrial cancer. Ginekol Pol . 1996 May;67(5):254-58.
  69. Creasman WT. Prognostic significance of hormone receptors in endometrial cancer. Cancer . 1993 Feb 15;71(suppl 4):1467-70.
  70. Friberg LG, Noren H. Prognostic value of steroid hormone receptors for 5-year survival in stage II endometrial cancer. Cancer . 1993 Jun 1;71(11):3570-4.
  71. Dai D, Wolf DM, et al. Progesterone inhibits human endometrial cancer cell growth and invasiveness: down-regulation of cellular adhesion molecules through progesterone B receptors. Cancer Res . 2002 Feb 1;62(3):881-6.
  72. Ehrlich CE, Young PC, et al. Steroid receptors and clinical outcome in patients with adenocarcinoma of the endometrium. Am J Obstet Gynecol . 1988 Apr;158(4):796-807.
  73. Ayoub J, udet-Lapointe P, et al. Efficacy of sequential cyclical hormonal therapy in endometrial cancer and its correlation with steroid hormone receptor status. Gynecol Oncol . 1988 Oct;31(2):327-37.
  74. Bokhman I, Stoliarova IV, et al. Effect of adjuvant hormonotherapy on the results of the radiation treatment of patients with cancer of the corpus uteri. Vopr Onkol . 1987;33(4):49-52.
  75. Lotze W, Richter P, et al. High-dose progesterone therapy in advanced endometrial cancer. Arch Geschwulstforsch . 1982;52(7):569-74.
  76. Thurzo L. Response of estrogen and progesterone receptors to treatment with large doses of progestogen (depo-provera) in endometrial cancer. Zentralbl Gynakol . 1990;112(17):1111-5.
  77. Kao MS. Management of recurrent endometrial carcinoma. Chang Gung Med J . 2004;27(9):639-45.
  78. Murphy KT, Rotmensch J, et al. Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys . 2003 Apr 1;55(5):1272-6.
  79. Li CZ, Wen ZQ, et al. Study on the treatment of high dose mifepristone and progesterone in endometrial carcinoma. Zhonghua Fu Chan Ke Za Zhi . 2003 Sep;38(9):552-55.
  80. Montz FJ, Bristow RE, et al. Intrauterine progesterone treatment of early endometrial cancer. Am J Obstet Gynecol . 2002 Apr;186(4):651-7.
  81. Piver MS. Progesterone therapy for malignant peritoneal cytology surgical stage I endometrial adenocarcinoma. Semin Oncol . 1988 Apr;15(suppl 1):50-2.
  82. Urbanski K, Karolewski K, et al. Adjuvant progestagen therapy improves survival in patients with endometrial cancer after hysterectomy: results of one-institutional prospective clinical trial. Eur J Gynaecol Oncol . 1993;14(suppl):98-104.
  83. La Vecchia C, Decarli A, et al. Nutrition and diet in the etiology of endometrial cancer. Cancer . 1986;57(6):1248-53.
  84. Benagiano G, Primiero FM, et al. Clinical profile of contraceptive progestins. Eur J Contracept Reprod Health Care . 2004 Sep;9(3):182-93.
  85. Neumann F. The physiological action of progesterone and the pharmacological effects of progestogens: a short review. Postgrad Med J . 1978;54(suppl 2):11-24.
  86. Warren MP, Shantha S. Uses of progesterone in clinical practice. Int J Fertil Womens Med . 1999 Mar;44(2):96-103.
  87. Apgar BS, Greenberg G. Using progestins in clinical practice. Am Fam Physician . 2000 Oct 15;62(8):1839-50.
  88. Mariani A, Dowdy SC, et al. High-risk endometrial cancer subgroups: candidates for target-based adjuvant therapy. Gynecol Oncol . 2004 Oct;95(1):120-6.
  89. Lewis GC Jr, Slack NH, et al. Adjuvant progestogen therapy in the primary definitive treatment of endometrial cancer. Gynecol Oncol . 1974 Aug;2(2-3):368-76.
  90. Yahata H, Hirakawa T, et al. Postoperative adjuvant chemotherapy with cisplatin, cyclophosphamide, and anthracycline (doxorubicin, epirubicin, pirarubicin) for endometrial cancer. Int J Clin Oncol . 2004 Aug;9(4):317-21.
  91. Terry P, Vainio H, et al. Dietary factors in relation to endometrial cancer: a nationwide case-control study in Sweden. Nutr Cancer . 2002;42(1):25-32.
  92. Littman AJ, Beresford SA, et al. The association of dietary fat and plant foods with endometrial cancer ( United States ). Cancer Causes Control . 2001;12(8):691-702.
  93. Lord RS, Bongiovanni B, et al. Estrogen metabolism and the diet-cancer connection: rationale for assessing the ratio of urinary hydroxylated estrogen metabolites. Altern Med Rev . 2002;7(2):112-29.
  94. Kris-Etherton PM, Harris WS, et al. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation . 2002 Nov 19;106(21):2747-57.
  95. Brooks JD, Ward WE, et al. Supplementation with flaxseed alters estrogen metabolism in postmenopausal women to a greater extent than does supplementation with an equal amount of soy. Am J Clin Nutr . 2004 Feb;79(2):318-25.
  96. Lucas EA, Wild RD , et al. Flaxseed improves lipid profile without altering biomarkers of bone metabolism in postmenopausal women. J Clin Endocrinol Metab . 2002 Apr;87(4):1527-32.
  97. Lemay A, Dodin S, et al. Flaxseed dietary supplement versus hormone replacement therapy in hypercholesterolemic menopausal women. Obstet Gynecol . 2002 Sep;100(3):495-504.
  98. Doll R. The lessons of life: keynote address to the nutrition and cancer conference. Cancer Res . 1992 Apr 1;52(suppl 7):2024s-2029s.
  99. McCullough ML, Giovannucci EL. Diet and cancer prevention. Oncogene . 2004 Aug 23;23(38):6349-64.
  100. Willett WC. Diet and cancer: an evolving picture. JAMA . 2005;293(2):233-34.
  101. Steinmetz KA, Potter JD. Vegetables, fruit, and cancer, II: mechanisms. Cancer Causes Control . 1991 Nov;2(6):427-42.
  102. Kobayashi Y, Itoh MT , et al. Melatonin binding sites in estrogen receptor-positive cells derived from human endometrial cancer. J Pineal Res . 2003;35(2):71-74.
  103. Shu XO, Zheng W, et al. A population-based case-control study of dietary factors and endometrial cancer in Shanghai , People's Republic of China . Am J Epidemiol . 1993;137(2):155-65.
  104. Tanaka S, Haruma K, et al. Effects of aged garlic extract (AGE) on colorectal adenomas: a double-blinded study. Hiroshima J Med Sci . 2004;53(3-4):39-45.
  105. Jacobs DR Jr, Meyer HE, et al. Consumption of whole grain foods and chronic disease. Tidsskr Nor Laegeforen . 2004;124(10):1399-1401.
  106. Nishino H, Tokuda H, et al. Cancer prevention by antioxidants. Biofactors . 2004;22(1-4):57-61.
  107. Khorram O, Lessey BA. Alterations in expression of endometrial endothelial nitric oxide synthase and alpha(v)beta(3) integrin in women with endometriosis. Fertil Steril . 2002 Oct;78(4):860-64.
  108. Cassidy A. Potential risks and benefits of phytoestrogen-rich diets. Int J Vitam Nutr Res . 2003;73(2):120-6.
  109. Goodman MT , Wilkens LR, et al. Association of soy and fiber consumption with the risk of endometrial cancer. Am J Epidemiol . 1997b;146(4):294-306.
  110. Horn-Ross PL, John EM, Canchola AJ, et al. Phytoestrogen intake and endometrial cancer risk. J Natl Cancer Inst. 2003 Aug 6;95(15):1158-64.
  111. Xu WH, Zheng W, et al. Soya food intake and risk of endometrial cancer among Chinese women in Shanghai: population based case-control study. BMJ . 2004 May;328(7451):1285.
  112. Bakuradze T, Boehm N, Janzowski C, et al. Antioxidant-rich coffee reduces DNA damage, elevates glutathione status and contributes to weight control: results from an intervention study. Mol Nutr Food Res. 2011 May;55(5):793-7.
  113. Hoelzl C, Knasmuller S, Wagner KH, et al. Instant coffee with high chlorogenic acid levels protects humans against oxidative damage of macromolecules. Mol Nutr Food Res. 2010 Dec;54(12):1722-33.
  114. Misik M, Hoelzl C, Wagner KH, et al. Impact of paper filtered coffee on oxidative DNA-damage: results of a clinical trial. Mutat Res. 2010 Oct 13;692(1-2):42-8.
  115. Jin UH, Lee JY, Kang SK, et al. A phenolic compound, 5-caffeoylquinic acid (chlorogenic acid), is a new type and strong matrix metalloproteinase-9 inhibitor: isolation and identification from methanol extract of Euonymus alatus. Life Sci. 2005 Oct 14;77(22):2760-9.
  116. Belkaid A, Currie JC, Desgagnés J, et al. The chemopreventive properties of chlorogenic acid reveal a potential new role for the microsomal glucose-6-phosphate translocase in brain tumor progression. Cancer Cell Int. 2006 Mar 27;6:7.
  117. Je Y, Giovannucci E. Coffee consumption and risk of endometrial cancer: Findings from a large up-to-date meta-analysis. Int J Cancer. 2011 Dec 20.
  118. Nagpal S. Retinoids: inducers of tumor/growth suppressors. J Invest Dermatol . 2004 Dec;123(6):xx-xxi.
  119. Nahum A, Hirsch K, et al. Lycopene inhibition of cell cycle progression in breast and endometrial cancer cells is associated with reduction in cyclin D levels and retention of p27(Kip1) in the cyclin E-cdk2 complexes. Oncogene . 2001;20(26):3428-36.
  120. Petridou E, Kedikoglou S, et al. Diet in relation to endometrial cancer risk: a case-control study in Greece. Nutr Cancer . 2002;44(1):16-22.
  121. Alberts DS, Jiang C, et al. Long-term follow-up of a phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer in the Southwest Oncology Group. Int J Gynecol Cancer . 2004 Mar-Apr;14(2):224-28.
  122. Carter CA, Pogribny M, et al. Effects of retinoic acid on cell differentiation and reversion toward normal in human endometrial adenocarcinoma (RL95-2) cells. Anticancer Res . 1996 Jan;16(1):17-24.
  123. Kakizoe T. Chemoprevention of cancer: focusing on clinical trials. Jpn J Clin Oncol . 2003 Sep;33(9):421-42.
  124. Meyskens FL Jr, Kopecky KJ, et al. Effects of vitamin A on survival in patients with chronic myelogenous leukemia: a SWOG randomized trial. Leuk Res . 1995 Sep;19(9):605-12.
  125. De Loecker W, Janssens J, et al. Effects of sodium ascorbate (vitamin C) and 2-methyl-1,4-naphthoquinone (vitamin K3) treatment on human tumor cell growth in vitro, II: synergism with combined chemotherapy action. Anticancer Res . 1993 Jan;13(1):103-6.
  126. Lenton KJ, Sane AT, et al. Vitamin C augments lymphocyte glutathione in subjects with ascorbate deficiency. Am J Clin Nutr . 2003 Jan;77(1):189-95.
  127. Golde DW. Vitamin C in cancer. Integr Cancer Ther . 2003 Jun;2(2):158-59.
  128. Alcain FJ, Buron MI. Ascorbate on cell growth and differentiation. J Bioenerg Biomembr . 1994 Aug;26(4):393-98.
  129. Head KA. Ascorbic acid in the prevention and treatment of cancer. Altern Med Rev . 1998 Jun;3(3):174-86.
  130. Block KI, Mead MN . Vitamin C in alternative cancer treatment: historical background. Integr Cancer Ther. 2003 Jun;2(2):147-54.
  131. Tamayo C, Richardson MA. Vitamin C as a cancer treatment: state of the science and recommendations for research. Altern Ther Health Med . 2003 May;9(3):94-101.
  132. Cameron E, Pauling L. Supplemental ascorbate in the supportive treatment of cancer: reevaluation of prolongation of survival times in terminal human cancer. Proc Natl Acad Sci U S A . 1978 Sep;75(9):4538-42.
  133. Gonzalez MJ, Miranda-Massari JR, et al. Orthomolecular oncology review: ascorbic acid and cancer 25 years later. Integr Cancer Ther . 2005 Mar;4(1):32-44.
  134. Bergman JM, Thompson LU, Dabrosin C. Flaxseed and its lignans inhibit estradiol-induced growth, angiogenesis, and secretion of vascular endothelial growth factor in human breast cancer xenografts in vivo. Clin Cancer Res. 2007 Feb 1;13(3):1061-7.
  135. Chen LH, Fang J, Li H, Demark-Wahnefried W, Lin X. Enterolactone induces apoptosis in human prostate carcinoma LNCaP cells via a mitochondrial-mediated, caspase-dependent pathway. Mol Cancer Ther. 2007 Sep;6(9):2581-90.
  136. Katsuda S, Yoshida M, Saarinen N, et al. Chemopreventive effects of hydroxymatairesinol on uterine carcinogenesis in Donryu rats. Exp Biol Med (Maywood). 2004 May;229(5):417-24.
  137. Simonneaux V, Ribelayga C. Generation of the melatonin endocrine message in mammals: a review of the complex regulation of melatonin synthesis by norepinephrine, peptides, and other pineal transmitters. Pharmacol Rev . 2003 Jun;55(2):325-95.
  138. Barrenetxe J, Delagrange P, et al. Physiological and metabolic functions of melatonin. J Physiol Biochem. 2004 Mar;60(1):61-72.
  139. Lissoni P, Chilelli M, et al. Five years survival in metastatic non-small cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: a randomized trial. J Pineal Res . 2003a Aug;35(1):12-5.
  140. Lissoni P, Malugani F, et al. Total pineal endocrine substitution therapy (TPEST) as a new neuroendocrine palliative treatment of untreatable metastatic solid tumor patients: a phase II study. Neuro Endocrinol Lett . 2003b Jun;24(3-4):259-62.
  141. Reiter RJ. Mechanisms of cancer inhibition by melatonin. J Pineal Res . 2004 Oct;37(3):213-4.
  142. Sanchez-Barcelo EJ, Cos S, et al. Melatonin-estrogen interactions in breast cancer. J Pineal Res . 2005 May;38(4):217-22.
  143. Chase JE, Gidal BE. Melatonin: therapeutic use in sleep disorders. Ann Pharmacother . 1997 Oct;31(10):1218-26.
  144. Dolberg OT, Hirschmann S, et al. Melatonin for the treatment of sleep disturbances in major depressive disorder. Am J Psychiatry . 1998 Aug;155(8):1119-21.
  145. Bespalov VG, Alexandrov VA, et al. Chemoprevention of mammary, cervix and nervous system carcinogenesis in animals using cultured Panax ginseng drugs and preliminary clinical trials in patients with precancerous lesions of the esophagus and endometrium. J Korean Med Sci . 2001 Dec;16(suppl):S42-S53.
  146. Fujimoto J, Sakaguchi H, et al. Inhibitory effect of ginsenoside-Rb2 on invasiveness of uterine endometrial cancer cells to the basement membrane. Eur J Gynaecol Oncol . 2001;22(5):339-41.
  147. Liu J, Burdette JE, et al. Evaluation of estrogenic activity of plant extracts for the potential treatment of menopausal symptoms. J Agric Food Chem . 2001 May;49(5):2472-9.
  148. Pearce PT, Zois I, et al. Panax ginseng and Eleuthrococcus senticosus extracts: in vitro studies on binding to steroid receptors. Endocrinol Jpn . 1982 Oct;29(5):567-73.
  149. Ginseng-HCC Chemopreventive Study Osaka Group. Study on chemoprevention of hepatocellular carcinoma by ginseng: an introduction to the protocol. J Korean Med Sci . 2001 Dec;16(suppl):S70-S74.
  150. Manusirivithaya S, Sripramote M, et al. Antiemetic effect of ginger in gynecologic oncology patients receiving cisplatin. Int J Gynecol Cancer . 2004 Nov;14(6):1063-9.
  151. Wiklund IK, Mattsson LA, et al. Effects of a standardized ginseng extract on quality of life and physiological parameters in symptomatic postmenopausal women: a double-blind, placebo-controlled trial. Swedish Alternative Medicine Group. Int J Clin Pharmacol Res . 1999;19(3):89-99.
  152. Yuan CS, Wei G, et al. Brief communication: American ginseng reduces warfarin's effect in healthy patients: a randomized, controlled trial. Ann Intern Med . 2004 Jul 6;141(1):23-7.
  153. Hirsch K, Danilenko M, et al. Effect of purified allicin, the major ingredient of freshly crushed garlic, on cancer cell proliferation. Nutr Cancer . 2000;38(2):245-54.
  154. Koda K, Miyazaki M et al. A randomized controlled trial of postoperative adjuvant immunochemotherapy for colorectal cancer with oral medicines.Int J Oncol . 2003;23(1):165-72.
  155. Noguchi K, Tanimura H et al. Polysaccharide preparation PSK augments the proliferation and cytotoxicity of tumor-infiltrating lymphocytes in vitro.Anticancer Res . 1995;15(2):255-8.
  156. Yokoe T, Iino Y et al. HLA antigen as predictive index for the outcome of breast cancer patients with adjuvant immunochemotherapy with PSK.Anticancer Res . 1997;17(4A):2815-8.
  157. Zhang H, Morisaki T et al. Protein-bound polysaccharide PSK inhibits tumor invasiveness by down-regulation of TGF-beta1 and MMPs.Clin Exp Metastasis . 2000;18(4):343-52.
  158. Ohwada S, Ogawa T, Makita F, et al. Beneficial effects of protein-bound polysaccharide K plus tegafur/uracil in patients with stage II or III colorectal cancer: analysis of immunological parameters. Oncol Rep. 2006 Apr;15(4):861-8.
  159. Fisher M, Yang LX. Anticancer effects and mechanisms of polysaccharide-K (PSK): implications of cancer immunotherapy. Anticancer Res. 2002 May;22(3):1737-54.
  160. Garcia-Lora A, Pedrinaci S, Garrido F. Protein-bound polysaccharide K and interleukin-2 regulate difference nuclear transcription factors in the NKL human natural killer cell line. Cancer Immunol Immunother. 2001 Jun;50(4):191-8.
  161. Pedrinaci S, Algarra I, Garrido F. Protein-bound polysaccharide (PSK) induces cytotoxic activity in the NKL human natural killer cell line. Int J Clin Lab Res. 1999;29(4):135-40.
  162. Okazaki A, Mitsuhashi N, Yamakawa M et al. [The effects of PS-K on long-term survival of uterine cervical cancer patients treated with radiation]. Gan No Rinsho. 1986 Feb;32(2):181-5.
  163. Sundstrom H. Annual variation of serum selenium in patients with gynaecological cancer during 1978-1983 in Finland: a low selenium area. Int J Vitam Nutr Res . 1985;55(4):433-8.
  164. Sundstrom H, Ylikorkala O, et al. Serum selenium and thromboxane in patients with gynaecological cancer. Carcinogenesis . 1986;7(7):1051-2.
  165. Sundstrom H, Yrjanheikki E, et al. Low serum selenium concentration in patients with cervical or endometrial cancer. Int J Gynaecol Obstet . 1984 Feb;22(1):35-40.
  166. Zhao L, Zhao W, et al. Correlation of the metabolism of oxygen free radical in ovary, uterine muscle and vein blood with the pathogenesis of endometriosis or endometrioma. Zhonghua Fu Chan Ke Za Zhi . 2001 May;36(5):299-301.
  167. Lou H, Wu R, et al. Relation between selenium and cancer of uterine cervix. Zhonghua Zhong Liu Za Zhi . 1995;17(2):112-4.
  168. Cunzhi H, Jiexian J, et al. Serum and tissue levels of six trace elements and copper/zinc ratio in patients with cervical cancer and uterine myoma. Biol Trace Elem Res . 2003;94(2):113-22.
  169. Drozdz M, Tomala J, et al. Concentration of selenium and vitamin E in the serum of women with malignant genital neoplasms and their family members. Ginekol Pol . 1989;60(6):301-5.
  170. Sundstrom H, Korpela H, et al. Supplementation with selenium, vitamin E and their combination in gynaecological cancer during cytotoxic chemotherapy. Carcinogenesis . 1989;10(2):273-8.
  171. Yang G, Zhou R. Further observations on the human maximum safe dietary selenium intake in a seleniferous area of China. J Trace Elem Electrolytes Health Dis . 1994 Dec;8(3-4):159-65.
  172. Kaur R, Sharma S, et al. Effect of sub-chronic selenium toxicosis on lipid peroxidation, glutathione redox cycle and antioxidant enzymes in calves. Vet Hum Toxicol . 2003 Aug;45(4):190-92.
  173. Salazar-Martinez E, Lazcano-Ponce E, et al. Dietary factors and endometrial cancer risk: results of a case-control study in Mexico . Int J Gynecol Cancer . 2005 Sep;15(5):938-45.
  174. Schaafsma G. The scientific basis of recommended dietary allowances for calcium. J Intern Med . 1992 Feb;231(2):187-94.
  175. American College of Obstetricians and Gynecologists. ACOG educational bulletin. Osteoporosis. Number 246, April 1998 (replaces No. 167, May 1992). American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet . 1998 Aug;62(2):193-201.
  176. Power ML, Holzman GB, et al. Knowledge and clinical practice regarding calcium nutrition among obstetrician-gynecologists. Obstet Gynecol . 1999 Sep;94(3):421-6.